Exelixis
EXEL
#2074
Rank
NZ$12.44 B
Marketcap
$43.64
Share price
0.67%
Change (1 day)
21.15%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.46

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.46. In 2022 the company made an earnings per share (EPS) of $0.92 a decrease over its 2021 EPS that were of $1.20.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.46-49.75%
2022$0.92-22.97%
2021$1.20100%
2020$0.60-65.09%
2019$1.71-53.91%
2018$3.72333.96%
2017$0.86-260.61%
2016-$0.53-58.75%
2015-$1.29-42.45%
2014-$2.255.3%
2013-$2.1343.48%
2012-$1.49-264.29%
2011$0.91-165.88%
2010-$1.37-32.54%
2009-$2.04-17.65%
2008-$2.4775.86%
2007-$1.41-25.64%
2006-$1.898.33%
2005-$1.75-42.86%
2004-$3.0530.34%
2003-$2.34-5.23%
2002-$2.47-0.65%
2001-$2.49-51.88%
2000-$5.17

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.66 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.14 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.94 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.42 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.87 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.77 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.01 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$16.16-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.36-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA